Cantor highly bullish on Amgen obesity drug, starts coverage at overweight
Cantor initiated Amgen (NASDAQ:AMGN) coverage with an overweight rating, asserting it was a “big believer” in the biotech ...
STAT3d
Amgen scores late-stage trial success for eczema and myasthenia gravis treatments, but faces stiff competition
Amgen on Tuesday reported that a pair of antibody drugs it is developing as treatments for immune-mediated diseases succeeded ...
JD Supra20h
Amgen Announces Third-party Data Breach Stemming from Incident at Sirva Relocation
On 4, 2024, Amgen, Inc. filed a notice of data breach with the Attorney General of Massachusetts after discovering that ...
Amgen: Pipeline Updates, Uplizna Performs And Rocatinlimab Underwhelms
Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...
Amgen gets early win in Regeneron lawsuit over Eylea biosimilar
Regeneron cannot immediately block U.S. sales of rival Amgen's proposed copy of its blockbuster eye-care drug Eylea, a ...
FiercePharma2d
With success in myasthenia gravis trial, Amgen's Uplizna looks set up to add new indication
As for Uplizna, Amgen said that it is initiating regulatory filing activities to set it up for approval to treat MG. Last ...
Amgen's muscular disorder drug meets main goal in late-stage study
Amgen said on Tuesday its experimental drug, rocatinlimab, met the main goals in a late stage study testing it as a treatment ...
Where Will Amgen Be in 5 Years?
Beyond MariTide, Amgen has a rich pipeline with more than 30 phase 3 programs. Some are for existing medicines seeking label ...
Analyst Expectations For Amgen's Future
Insights from analysts' 12-month price targets are revealed, presenting an average target of $326.38, a high estimate of $381 ...
FierceBiotech3d
Amgen reports first phase 3 win for $400M eczema drug, but Dupixent rivalry doubts remain
Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the | Amgen has shared the first phase ...